MiNK Therapeutics Files 10-Q for Period Ending March 31, 2024
Ticker: INKT · Form: 10-Q · Filed: May 14, 2024 · CIK: 1840229
Sentiment: neutral
Topics: 10-Q, MiNK Therapeutics, Financials, R&D, SEC Filing
TL;DR
<b>MiNK Therapeutics filed its Q1 2024 10-Q, detailing financial data and corporate history.</b>
AI Summary
MiNK Therapeutics, Inc. (INKT) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. MiNK Therapeutics, Inc. filed a 10-Q for the quarter ended March 31, 2024. The company's business address is 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010. The filing includes data related to Research and Development Expense, Retained Earnings, and Accumulated Other Comprehensive Income. Key dates mentioned include 2024-03-31 for financial reporting and 2024-05-14 for the filing date. The company was formerly known as AgenTus Therapeutics, Inc., with a name change on 20210112.
Why It Matters
For investors and stakeholders tracking MiNK Therapeutics, Inc., this filing contains several important signals. This filing provides an update on MiNK Therapeutics' financial position and operational activities for the first quarter of 2024, crucial for investors tracking the company's performance. The inclusion of specific financial line items like Research and Development Expense and Retained Earnings offers insight into the company's investment in future growth and its current profitability status.
Risk Assessment
Risk Level: medium — MiNK Therapeutics, Inc. shows moderate risk based on this filing. The filing is a standard 10-Q, which provides a snapshot of financial health but lacks forward-looking guidance or significant new developments that would indicate immediate high risk or reward.
Analyst Insight
Monitor future filings for updates on R&D expenses and any new agreements or financial transactions that could impact the company's trajectory.
Key Numbers
- 2024-03-31 — Reporting Period End Date (Conformed period of report)
- 2024-05-14 — Filing Date (Filed as of date)
- 20210112 — Date of Name Change (Former company name)
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Filer name
- AgenTus Therapeutics, Inc. (company) — Former company name
- 2024-03-31 (date) — Conformed period of report
- 2024-05-14 (date) — Filed as of date
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010 (address) — Business address
- Agenus Inc. (company) — Related entity in agreements
- AtlantClinical Ltd (company) — Related entity in R&D arrangements
FAQ
When did MiNK Therapeutics, Inc. file this 10-Q?
MiNK Therapeutics, Inc. filed this Quarterly Report (10-Q) with the SEC on May 14, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by MiNK Therapeutics, Inc. (INKT).
Where can I read the original 10-Q filing from MiNK Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by MiNK Therapeutics, Inc..
What are the key takeaways from MiNK Therapeutics, Inc.'s 10-Q?
MiNK Therapeutics, Inc. filed this 10-Q on May 14, 2024. Key takeaways: MiNK Therapeutics, Inc. filed a 10-Q for the quarter ended March 31, 2024.. The company's business address is 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010.. The filing includes data related to Research and Development Expense, Retained Earnings, and Accumulated Other Comprehensive Income..
Is MiNK Therapeutics, Inc. a risky investment based on this filing?
Based on this 10-Q, MiNK Therapeutics, Inc. presents a moderate-risk profile. The filing is a standard 10-Q, which provides a snapshot of financial health but lacks forward-looking guidance or significant new developments that would indicate immediate high risk or reward.
What should investors do after reading MiNK Therapeutics, Inc.'s 10-Q?
Monitor future filings for updates on R&D expenses and any new agreements or financial transactions that could impact the company's trajectory. The overall sentiment from this filing is neutral.
Risk Factors
- Research and Development Expenses [medium — financial]: The filing details research and development expenses, indicating ongoing investment in product development.
- Retained Earnings [medium — financial]: Information on retained earnings provides insight into the company's cumulative profitability.
Key Dates
- 2024-03-31: Quarterly Reporting Period End — Financial data snapshot for Q1 2024.
- 2024-05-14: 10-Q Filing Date — Official submission date of the quarterly report.
- 2021-01-12: Company Name Change — Marks the transition from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides investors with a timely update on the company's financial performance and condition.)
- Research and Development Expense
- Costs incurred by a company in the process of developing new products or services. (Indicates the company's investment in innovation and future growth potential.)
Filing Stats: 4,404 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2024-05-14 07:28:28
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT Nasdaq Capital Marke
Filing Documents
- inkt-20240331.htm (10-Q) — 788KB
- inkt-ex31_1.htm (EX-31.1) — 14KB
- inkt-ex31_2.htm (EX-31.2) — 14KB
- inkt-ex32_1.htm (EX-32.1) — 10KB
- 0000950170-24-059081.txt ( ) — 3778KB
- inkt-20240331.xsd (EX-101.SCH) — 705KB
- inkt-20240331_htm.xml (XML) — 420KB
Financial Statements (Unaudited)
Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Deficit for the three months ended March 31, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 5 Notes to Unaudited Interim Condensed Consolidated Financial Statements 6 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 12 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 17 Item 4.
Controls and Procedures
Controls and Procedures 17 PART II. OTHER INFORMATION 18 Item 1.
Legal Proceedings
Legal Proceedings 18 Item 1A.
Risk Factors
Risk Factors 18 Item 5. Other Information 18 Item 6. Exhibits 19
—FINANCI AL INFORMATION
PART I—FINANCI AL INFORMATION
Financi al Statements
Item 1. Financi al Statements. MINK THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDAT ED BALANCE SHEETS (Unaudited) March 31, 2024 December 31, 2023 ASSETS Cash and cash equivalents $ 5,817,080 $ 3,367,229 Prepaid expenses 59,394 53,111 Other current assets 122,477 177,964 Total current assets 5,998,951 3,598,304 Equipment, net of accumulated depreciation of $ 545,095 and $ 495,638 at March 31, 2024 and December 31, 2023, respectively 894,992 953,977 Total assets $ 6,893,943 $ 4,552,281 LIABILITIES AND STOCKHOLDERS' DEFICIT Accounts payable $ 3,486,999 $ 3,911,973 Accrued liabilities 5,282,707 5,037,361 Other current liabilities 2,338,554 2,453,251 Total current liabilities 11,108,260 11,402,585 Related party note 4,211,566 — Other long-term liabilities 31,600 48,072 Due to related parties 11,841,724 11,157,073 Commitments and contingencies STOCKHOLDERS' DEFICIT Common stock, par value $ 0.00001 per share; 150,000,000 shares authorized; 34,699,056 and 34,599,119 shares issued at March 31, 2024 and December 31, 2023, respectively 347 346 Additional paid-in capital 117,296,454 115,772,085 Accumulated other comprehensive loss ( 385,780 ) ( 430,947 ) Accumulated deficit ( 137,210,228 ) ( 133,396,933 ) Total stockholders' deficit ( 20,299,207 ) ( 18,055,449 ) Total liabilities and stockholders' deficit $ 6,893,943 $ 4,552,281 See accompanying notes to unaudited condensed consolidated financial statements. 1 MINK THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Three Months Ended March 31, 2024 2023 Operating expenses: Research and development $ 2,549,482 $ 4,193,562 General and administrative 1,280,432 1,660,534 Operating loss ( 3,829,914 ) ( 5,854,096 ) Other income, net: Interest income,